1. Introduction {#s0005}
===============

The first description of Merkel Cell Carcinoma (MCC) was in 1972 by Toker explaining the tumor as a trabecular carcinoma of the skin ([@bb0075]). Today we know that MCC is a rare, highly aggressive neuroendocrine malignancy occurring mostly in elderly individuals. The etiology is not totally known, but general immunosuppression and ultraviolet light exposure seem to be risk factors and the Merkel cell polyomavirus, a DNA virus, seems to be a contributing factor of the occurrence of MCC. In nearly 80% of MCC cases the virus could be found. But depending on the different regions all over the world the incidence of virus positive compared with virus negative MCC differs ([@bb0015]). With 30% the mortality rate is higher than in malignant melanoma ([@bb0050]).

The incidence rate in the USA is about 0.44 cases per 100'000 and has increased for the last years ([@bb0050]; [@bb0035]). 50% of MMC occur in the head and neck region followed by trunk and extremities. The clinical appearance is a red-violet cutaneous nodule with a smooth surface, which is painless but rapidly growing ([@bb0060]). Palpable regional lymphadenopathy with lymph node metastases are frequent. Distant metastases occur in the lungs, the liver, the bones and the brain. There are only a few case reports on metastases to the gastrointestinal system, the heart, the tonsil, the spinal cord, the testis, the orbita or the ovaries. Metastases of MCC have also been found in lymph nodes with unknown primary tumor ([@bb0045]). To our knowledge just three cases with ovarian metastases of MCC have been described until now. In the first two cases the primary tumor was found in the inguinal skin, in the third case in the periauricular skin ([@bb0025]; [@bb0010]; [@bb0005]). Metastases from MCC spreading to the ovaries are unusual. Common metastases in the ovaries descend from colon, stomach, appendix, breast and genitourinary tract ([@bb0005]). Metastatic MCC has poor prognosis. Two years after diagnosis the mortality rate is 30%, five years after 50% ([@bb0005]; [@bb0040]).

2. Case report {#s0010}
==============

We describe the case of an 80-year-old woman with complete resection of MCC on the cheek six years ago. It is unknown if there was a lymph node biopsy or a radiotherapy after the resection of the primary tumor. She reported in our outpatient clinic with increasing abdominal pain. In the preoperative examination a solid tumor of the left ovary was suspected ([Fig. 1](#f0005){ref-type="fig"}). The cancer-antigen 125 (CA-125) was normal. There was no indication of recurrence or other metastases of the resected MCC. The patient received abdominal hysterectomy and adnexectomy on both sides. The left ovary was an enlarged solid mass with a smooth, intact capsule. The tumor showed a torsion explaining the abdominal pain. There was no sign of other intraabdominal pathology. Histological findings showed a small-cell carcinoma with necrosis and intact capsule ([Fig. 2](#f0010){ref-type="fig"}). Immunohistochemically the tumor was positive for epithelial membrane antigen (EMA), cytokeratin 20 (CK20), chromogranin, synaptophysin and negative for thyroid transcription factor 1 (TTF-1). Diagnosis of MCC metastasis was indisputable. A virus test was not made. A few days after surgery the patient reported with new pain in her right femur, although she did not show any other symptoms before laparotomy except abdominal pain. Radiological examinations confirmed a pathological distal femur fracture due to metastatic bone infiltration. After osteosynthesis the follow-up was uneventful. In an additional computed tomography multiple lesions, likely to be metastases, were discovered. They were in the left suprarenal gland and outside of the pelvis in the left musculus piriformis. Nevertheless the patient refused radiation or chemotherapy. Six months later she reported again with discomfort because of multiple new cutaneous and subcutaneous metastases. Her quality of life was still good and so she decided to have the disturbing lesions on the thorax and supraclavicular removed. In a total body positron emission tomography-computed tomography (PET-CT) another metastasis in the heart was diagnosed. In the following months the patient agreed to the best supportive care.Fig. 1Ultrasound image with the solid tumor of the left ovary (6 in. diameter).Fig. 1Fig. 2Scheme of MCC with scant cytoplasm and round nuclei (hematoxylin and eosin stain) ([@bb0005]).Fig. 2

3. Discussion {#s0015}
=============

To our knowledge just three cases with ovarian metastasis of MCC have been described. In the first two cases the primary tumor was in the inguinal skin. In the third case it was periauricular. Our case is the second with distant metastasis in the ovary spreading of primary tumor from the skin of the head. In the three previously described cases the metastases were diagnosed within 15 months after the first treatment ([@bb0025]; [@bb0010]; [@bb0005]). In our case the ovarian metastasis occurred astonishingly not earlier than six years after the primary disease. MCC often occurs in elderly patients on sun-exposed areas of the skin. Immunosuppression due to HIV-infection, chemotherapy, organ transplantation or malignant lymphoma increase the risk of MCC. Merkel cell polyomavirus seems to be a contributing factor of the occurrence of MCC ([@bb0005]). The origin of MCC is not exactly known. A neural crest origin of the Merkel cells is suspected. It would explain the neuro-endocrine and epithelial differentiation of the tumors ([@bb0090]).

After diagnosis of MCC a preoperative staging will be done by total body positron emission tomography-computed tomography (PET-CT) ([@bb0080]).

Histopathological findings are a monotonous tumor cell population with large prominent nuclei and scant cytoplasma. Three histological subtypes exist: trabecular, intermediate and small cell MCC, but the utility of this classification is not clear ([@bb0060]). Immunohistochemically MCC is positive for EMA, CK20 and neuroendocrine markers like synaptophysin and chromogranin. MCC is negative for TTF-1 to distinguish it from pulmonary small-cell carcinoma. With these markers a clear classification as MCC is possible ([@bb0060]; [@bb0045]; [@bb0005]; [@bb0085]).

In our case the ovarian metastasis was positive for EMA, CK20, chromogranin, synaptophysin and negative for TTF-1.

The treatment of MCC depends on tumor size, localization and stage, but there is no consensus on the therapy of MCC. 2010 the first staging system for MCC was published and since then a few updates have been done. Carcinoma in situ is stage 0, a tumor ≤2 cm stage I and bigger tumor stage II. Stage III is reserved for nodal positive disease and stage IV for distant metastasis. The TNM classification exists too ([@bb0030]).

The primary treatment for early stages is surgery with sentinel node biopsy or complete lymph node dissection. Clinical nodal negative patient receive sentinel node biopsy and adjuvant radiation therapy. In clinical or histological node-positive disease complete lymph node dissection is recommended. If surgery of the primary tumor is not possible or the sentinel node is positive and complete lymph node dissection is not carried out, radiation therapy is also possible. Furthermore radiotherapy can be utilized as a palliative treatment ([@bb0060]; [@bb0080]). Because of the rarity of MCC there is a lack of experience of metastases, most publications are case reports and there are no controlled randomized trials about chemotherapy ([@bb0005]; [@bb0040]; [@bb0080]). Chemotherapy is reserved for metastatic disease and is similar to the treatment of small-cell lung carcinomata because of the same neuroendocrine origin of MCC. Common regimes include cisplatin or carboplatin, with etoposide and topotecan. ([@bb0060]). Immunotherapy with e.g. immune checkpoint inhibitors or cytokines are used in clinical trials. Other immunotherapies are described but not yet established ([@bb0060]; [@bb0080]; [@bb0085]; [@bb0055]). Potential therapeutic targets are currently under investigation. In clinical trials for the treatment of MCC tyrosine kinase inhibitors, somatostatin analogs and mammalian target of rapamycin inhibitors are being used. There is a case report of clinical response to idelalisib, a phosphoinositide 3-kinase inhibitor, in a patient with MCC. Gavvovidis et al. describe T-cell based immunotherapy. MCC cells can be targeted by Merkel Cell polyomavirus T antigen-specific T-cell receptors ([@bb0070]; [@bb0020]; [@bb0065])

4. Conclusion {#s0020}
=============

MCC is a rare tumor with an increasing incidence in the last years. It is a highly aggressive cutaneous and mucosal malignancy with frequent recurrence, lymph node and distant metastases. Each small, blue and round cell tumor could be an MCC. The histological and immunohistological examinations are very important to diagnose these metastases. Distant metastases of MCC to the ovaries are extremely rare ([@bb0005]).

In the described case the six-year-disease-free survival after the first tumor excision was extraordinarily long. In the previously published cases the first metastases were found 15 months after the diagnosis of MCC ([@bb0005]). The first sign of a disease recurrence with abdominal pain due to ovarian metastasis is astonishing. Even if the primary treatment is successful, regular follow-up examinations are important to recognize recurrence and metastases. There should be a clinical follow-up examination every 3 to 4 months for the first 2 to 3 years after treatment. After 3 years examinations can follow every 6 to 12 months. There are no guidelines for imaging frequency. Imaging depends on the patient\'s symptoms and risk factors, e.g. nodal disease or immunosupression. Positron emission tomography/computed tomography has the highest sensitivity for detecting subclinical disease ([@bb0070]). Our case is the second description of distant metastasis to the ovary spreading from a tumor in the skin of the head and neck.

There is little knowledge of treatments for metastatic MCC. Most recommendations result from case reports and it is unlikely that there will ever be a prospective trial because this is a very rare disease.
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